3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

1. Pérez-García, J.M.
2. Cortés, J.
3. Ruiz-Borrego, M.
4. Colleoni, M.
5. Stradella, A.
6. Bermejo, B.
7. Dalenc, F.
8. Escrivá-de-Romaní, S.
9. Calvo Martínez, L.
10. Ribelles, N.
11. Marmé, F.
12. Cortés, A.
13. Albacar, C.
14. Gebhart, G.
15. Prat, A.
16. Kerrou, K.
17. Schmid, P.
18. Braga, S.
19. Di Cosimo, S.
20. Gion, M.
21. Antonarelli, G.
22. Popa, C.
23. Szostak, E.
24. Alcalá-López, D.
25. Gener, P.
26. Rodríguez-Morató, J.
27. Mina, L.
28. Sampayo-Cordero, M.
29. Llombart-Cussac, A.
30. Show all authors +